Global mAb Biosimilars Market 2016-2020

Publisher Name :
Date: 23-Sep-2016
No. of pages: 103
Inquire Before Buying

Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.

The analysts forecast spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of more than 57% during the period 2015-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.

The market is divided into the following segments based on geography:


  • Europe

  • Asia

  • ROW


The report, Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • Biocon

  • Celltrion

  • Dr. Reddy's Laboratories

  • Hospira


Other prominent vendors


  • 3SBio

  • Accord Healthcare

  • AET Biotech

  • Allergan

  • Alvartis Pharma

  • Amega Biotech

  • Amgen

  • Apotex

  • Aspen

  • AstraZeneca

  • Aurobindo Pharma

  • Baxter

  • Bharat Serums

  • Bio Sidus

  • Biogen

  • Bionovis

  • Bioton

  • BioXpress Therapeutics

  • Boehringer Ingelheim

  • Boston Oncology

  • Cipla

  • Coherus Biosciences

  • Daiichi Sankyo

  • Emcure Pharmaceuticals

  • Gedeon Richter

  • GeneScience Pharmaceuticals

  • GSK

  • Hetero Drugs

  • iBio

  • Intas Pharmaceuticals

  • JCR Pharmaceuticals

  • LG Lifesciences

  • Lonza

  • Merck

  • Mitsubishi Tanabe Pharma

  • Momenta Pharmaceuticals

  • Mylan

  • Natco Pharma

  • Novartis

  • Pfenex

  • Pfizer

  • Ranbaxy Laboratories

  • Roche Holding

  • Samsung Biologics

  • Sanofi

  • Synthon


Market driver


  • •Rise in number of patent expiries

  • For a full, detailed list, view our report


Market challenge


  • Physicians' reluctance to prescribe biosimilars

  • For a full, detailed list, view our report


Market trend


  • Emergence of biosimilars

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2020 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Global mAb Biosimilars Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings
Assumptions

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights
Biosimilars: Overview
Comparative analysis of generic small molecules and biosimilars
Biosimilars market opportunities
Challenges for new entrants
Bio-betters

PART 05: Pipeline portfolio

PART 06: Market landscape
Market overview
Five forces analysis

PART 07: Market segmentation by application
Global chronic and autoimmune diseases mAb biosimilars market
Global oncology mAb biosimilars market

PART 08: Geographical segmentation
Global mAb biosimilars market by geographical segmentation 2015-2020
mAb biosimilars market in Europe
mAb biosimilars market in Asia
mAb biosimilars market in rest of the world

PART 09: Market drivers
Rise in number of patent expiries
Need for cost-effective treatment
Reimbursement benefits for biosimilars
Favorable government regulations

PART 10: Impact of drivers

PART 11: Market challenges
Physicians' reluctance to prescribe biosimilars
Multiple manufacturing complexities
Risks related to drug failure
Limited availability of biosimilar products
Difficulties in patient recruitment for clinical trials

PART 12: Impact of drivers and challenges

PART 13: Market trends
Emergence of biosimilars
Outsourcing of manufacturing activities
Need for high investment in R&D
High growth in the emerging markets
Rising number of strategic collaborations

PART 14: Vendor landscape
Competitive scenario

PART 15: Key vendor analysis
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
Other prominent vendors

PART 16: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Global mAb biosimilars market: Snapshot
Exhibit 03: Global mAb biosimilars market: Growth analysis
Exhibit 04: Global mAb biosimilars market: Key buying criteria 2015
Exhibit 05: Global mAb biosimilars market: Timeline 2014-2020
Exhibit 06: Global mAb biosimilars market: Impact of key customer segments 2015
Exhibit 07: Definition of biosimilars by agencies
Exhibit 08: Comparison between generic small molecules and biosimilars
Exhibit 09: Impact of biosimilars cost savings on different sectors
Exhibit 10: Factors affecting success of biosimilars
Exhibit 11: Biosimilars industry: Point-of-view
Exhibit 12: Factors influencing uptake of biosimilars
Exhibit 13: Global mAb biosimilars market: Strategic factors for new market entrants
Exhibit 14: Challenges for new entrants
Exhibit 15: Bio-betters and its impact on market
Exhibit 16: Global mAb biosimilars market: Pipeline snapshot 2015
Exhibit 17: Pipeline portfolio: Global mAb biosimilars market 2015
Exhibit 18: Patent expiry in key mAb biosimilars markets 2000-2020
Exhibit 19: Global mAb biosimilars market: Developed and emerging markets 2015
Exhibit 20: Global mAb biosimilars market 2015-2020 ($ millions)
Exhibit 21: Biosimilars: Savings potential in five European countries and US ($ billions) 2016-2020
Exhibit 22: Global spending on mAb biosimilars 2010-2020 ($ billions)
Exhibit 23: Global mAb biosimilars market: Key metrics analysis snapshot
Exhibit 24: Current and future trends in global mAb biosimilars market
Exhibit 25: Factors influencing the global mAb biosimilars market 2015
Exhibit 26: Five forces analysis
Exhibit 27: Global mAb biosimilars market: Segmentation by application (2015-2020)
Exhibit 28: Applications of mAb biosimilars and its impact on growth of market
Exhibit 29: Global mAb biosimilars market segmentation: Growth cycle analysis
Exhibit 30: Population aged 60 years and over (millions)
Exhibit 31: Global chronic and autoimmune diseases mAb biosimilars market 2015-2020 ($ millions)
Exhibit 32: Opportunity analysis of chronic and autoimmune diseases mAb biosimilars market by application
Exhibit 33: Global incidence of cancer 2015-2020 (millions)
Exhibit 34: Global oncology mAb biosimilars market 2015-2020 ($ millions)
Exhibit 35: Opportunity analysis of global oncology mAb biosimilars market by type of application
Exhibit 36: Global mAb biosimilars market segmentation by application 2015
Exhibit 37: Global mAb biosimilars market by geography: Outlook 2015-2020
Exhibit 38: Global mAb biosimilars market by geography 2015
Exhibit 39: Market penetration of originators and biosimilars by region/country
Exhibit 40: Global mAb biosimilars market landscape: Country analysis
Exhibit 41: mAb biosimilars market in Europe: Opportunity analysis
Exhibit 42: mAb biosimilars market in Europe 2015-2020 ($ millions)
Exhibit 43: PEST analysis: mAb biosimilars market in Europe 2015
Exhibit 44: mAb biosimilars market in Asia: Opportunity analysis
Exhibit 45: mAb biosimilars market in Asia 2015-2020 ($ millions)
Exhibit 46: PEST analysis: mAb biosimilars market in Asia 2015
Exhibit 47: mAb biosimilars market in rest of the world: Opportunity analysis
Exhibit 48: mAb biosimilars market in rest of the world 2015-2020 ($ millions)
Exhibit 49: Benefits of mAb biosimilars to US healthcare system
Exhibit 50: PEST analysis: mAb biosimilars market in rest of the world 2015
Exhibit 51: Impact of drivers and challenges on global mAb biosimilars market
Exhibit 52: Patent analysis of mAb in the US
Exhibit 53: Patent analysis of biologicals in Europe
Exhibit 54: Impact of drivers
Exhibit 55: Physicians' reluctance to prescribe biosimilars: Key reasons
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Global mAb biosimilars market: Impact assessment of key trends
Exhibit 58: Competitive assessment of vendors
Exhibit 59: Key vendors: Geographical presence 2015
Exhibit 60: Major vendors in global mAb biosimilars market: Mergers, acquisitions, and partnerships
Exhibit 61: Biocon profile
Exhibit 62: Biocon: Metrics analysis
Exhibit 63: Biocon growth strategy matrix
Exhibit 64: Biocon: Opportunity assessment
Exhibit 65: Celltrion profile
Exhibit 66: Celltrion: Metrics analysis
Exhibit 67: Celltrion growth strategy matrix
Exhibit 68: Celltrion: opportunity assessment
Exhibit 69: Dr. Reddy's Laboratories profile
Exhibit 70: Dr. Reddy's Laboratories: Metrics analysis
Exhibit 71: Dr. Reddy's Laboratories growth strategy matrix
Exhibit 72: Dr. Reddy's Laboratories Opportunity assessment
Exhibit 73: Hospira profile
Exhibit 74: Hospira: Metrics analysis
Exhibit 75: Hospira growth strategy matrix
Exhibit 76: Hospira opportunity growth assessment

  • Global Luxury Apparels Market To Do Well Owing To Numerous International Brands
    The global luxury apparels market is fired by the intensifying number of fashion marques and many designers getting wide-ranging clienteles in the form of cost-effective products. The global luxury apparels market was at US$1, 8842.69 million in 2015 and is forecast to reach US$60,793.7 million by the end of 2024. This segment of luxury goods [...]
  • Global Health and Wellness Market Boosted By Organic Products and Wearables
    Healthcare has constantly been a profitable area where buyers spend belligerently. But now, with increasing disposable earnings amid the city population and ground-breaking approaches and innovative products being developed, the overall health and wellness market is estimated for a healthy prospect. The health and wellness market is presently very dynamic owing to growing alertness amongst [...]
  • Increasing New Outlets And Striking Offers To Drive Global Pizza Market
    The global pizza market is predicted to grow at a steady CAGR of about 3% by 2020. Pizza has been gaining massive acceptance globally in the last few years. Consequently, the global pizza market is anticipated to observer considerable progress in the coming years. The growing number of pizzerias is one of the major elements [...]
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016
    Published: 01-Nov-2016        Price: US 1450 Onwards        Pages: 79
    DelveInsight's, "Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016" discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars holds a future Scope and potential in the market. It highlights the market trends, regulatory requirements for US and EU and key domestic players. Report provides an insight on Insulin Biosimilars that are under development for Type 1 and Type 2 Diabetes with an in......
  • China Biologics and Biosimilars Market Research Report 2016
    Published: 26-Oct-2016        Price: US 3200 Onwards        Pages: 123
    Notes: Sales, means the sales volume of Biologics and Biosimilars Revenue, means the sales value of Biologics and Biosimilars This report studies Biologics and Biosimilars in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Pfizer - Roche - Amgen - AbbVie - Sanofi - Johnson & Johnson - Novo Nordisk - Novartis......
  • China Biosimilars Market Research Report 2016
    Published: 25-Oct-2016        Price: US 3200 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Laser Capture Microdissection Revenue, means the sales value of Laser Capture Microdissection This report studies Biosimilars in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Sandoz International GmbH (Germany) - Hospira, Inc. (U.S.) - Teva Pharmaceutical Industries Ltd. (Israel) - Dr. Reddy's Lab......
  • China Biosimilar Drug Market by Manufacturers, Type and Application, Forecast to 2021
    Published: 04-Oct-2016        Price: US 4480 Onwards        Pages: 101
    Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine. Scope of the Report: This report focuses on the Biosimilar Drug in China market. This repo......
  • Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis
    Published: 03-Oct-2016        Price: US 1350 Onwards        Pages: 177
    The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020.  With the continuous increasing demand for biologics, manufacturers are looking for novel strategies that will help them attain maximum returns on investment. Biosimilars are seen as the key weapon to curbing soar......
  • Global Biologics and Biosimilars Market Professional Survey Report 2016
    Published: 08-Aug-2016        Price: US 3500 Onwards        Pages: 110
    Notes: Production, means the output of Biologics and Biosimilars Revenue, means the sales value of Biologics and Biosimilars This report studies Biologics and Biosimilars in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production......
  • United States Adalimumab Biosimilar Industry 2016 Market Research Report
    Published: 02-Aug-2016        Price: US 3800 Onwards        Pages: 130
    The United States Adalimumab Biosimilar Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Adalimumab Biosimilar industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Adalimumab Biosimilar market analysis is provided for the United States markets including development trends, competitive landscape analysis, and key regions development s......
  • Global Biosimilars Market 2016-2020
    Published: 01-Aug-2016        Price: US 2500 Onwards        Pages: 152
    Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator's product. They have many similarities, but are not identical to, the reference biopharmaceutical product. The analyst forecast global biosimilars market to grow at a CAGR of 5......
  • China Adalimumab Biosimilar Industry 2016 Market Research Report
    Published: 25-Jul-2016        Price: US 3200 Onwards        Pages: 130
    The China Adalimumab Biosimilar Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Adalimumab Biosimilar industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Adalimumab Biosimilar market analysis is provided for the China markets including development trends, competitive landscape analysis, and key regions development status. ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs